ranalexin

an antimicrobial peptide from bullfrog Rana catesbeiana; a 20-amino acid peptide which contains a single intramolecular disulfide bond that forms a heptapeptide ring within the molecule; amino acid sequence given in first source

Networked: 7 relevant articles (3 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - ranalexin: 7
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - ranalexin: 7

Experts

1.	Cirioni, O: 3 articles (10/2001 - 11/2000)
2.	Ghiselli, R: 3 articles (10/2001 - 11/2000)
3.	Giacometti, A: 3 articles (10/2001 - 11/2000)
4.	Mocchegiani, F: 3 articles (10/2001 - 11/2000)
5.	Saba, V: 3 articles (10/2001 - 11/2000)
6.	Scalise, G: 3 articles (10/2001 - 11/2000)
7.	Coote, Peter J: 2 articles (06/2010 - 04/2010)
8.	Goffi, L: 2 articles (12/2000 - 11/2000)
9.	Riva, A: 2 articles (12/2000 - 11/2000)
10.	Aleinein, Rasha Abou: 1 article (04/2013)

Related Diseases

1.	Infections 06/01/2010 - "In a mouse model of systemic infection, ranalexin with lysostaphin reduced MRSA kidney burden by ca. 1log(10)CFU/g compared with untreated controls or treatment with ranalexin or lysostaphin alone. " 12/01/2000 - "A rat model was used to investigate the efficacies of two peptides, ranalexin and buforin II, in the prevention of vascular prosthetic graft infections. " 11/01/2000 - "A rat model was used to investigate the efficacy of two polycationic peptides, ranalexin and buforin II, in the prevention of vascular prosthetic graft infection due to methicillin-resistant Staphylococcus epidermidis with intermediate resistance to glycopeptides. " 06/01/2010 - "In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections."
2.	Endotoxemia 10/01/2001 - "Monodose ranalexin treatment prevents bacterial growth, endotoxemia, and mortality in rats with septic shock." 10/01/2001 - "Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia."
3.	Wounds and Injuries (Trauma) 06/01/2010 - "Ranalexin and lysostaphin could be incorporated in wound dressings for the prevention and treatment of topical S. " 06/01/2010 - "In a rabbit model of wound infection, ranalexin with lysostaphin reduced MRSA in the wound by ca. 3.5log(10) colony-forming units (CFU) compared with the untreated control. " 06/01/2010 - "In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections."
4.	Septic Shock (Toxic Shock Syndrome) 10/01/2001 - "Monodose ranalexin treatment prevents bacterial growth, endotoxemia, and mortality in rats with septic shock." 10/01/2001 - "A rat model was used to investigate the efficacy of a polycationic peptide, the polymyxin-like ranalexin, in the prevention of lethality in a rat model of septic shock. "
5.	Wound Infection (Wound Infections) 06/01/2010 - "In a rabbit model of wound infection, ranalexin with lysostaphin reduced MRSA in the wound by ca. 3.5log(10) colony-forming units (CFU) compared with the untreated control. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	buforin II
3.	Polymyxins (Polymyxin)
4.	Endopeptidases
5.	Methicillin (Metin)
6.	Lysostaphin
7.	Glycopeptides
8.	Antimicrobial Peptides
9.	Macrolides
10.	Teicoplanin